

Ana Bosch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11390594/publications.pdf>

Version: 2024-02-01

20
papers

1,604
citations

623734

14
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

3360
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12598-e12598.	1.6	0
2	Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study. <i>Carcinogenesis</i> , 2021, 42, 1314-1325.	2.8	8
3	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 26.	5.0	19
4	Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer. <i>Molecular Cell</i> , 2021, 81, 1453-1468.e12.	9.7	31
5	An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5557-5565.	7.0	26
6	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. <i>Nature Communications</i> , 2021, 12, 5112.	12.8	38
7	Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1360.	7.1	30
8	Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. <i>Nature Communications</i> , 2020, 11, 3747.	12.8	53
9	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. <i>Cell Reports</i> , 2019, 27, 3573-3586.e7.	6.4	66
10	Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. <i>Nature Medicine</i> , 2019, 25, 1526-1533.	30.7	218
11	The Strategy of PIking a Target: What Is AKtually Most Effective?. <i>Clinical Cancer Research</i> , 2018, 24, 2029-2031.	7.0	6
12	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	7.7	80
13	High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer. <i>Oncotarget</i> , 2016, 7, 59640-59651.	1.8	65
14	Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. <i>Molecular and Cellular Oncology</i> , 2014, 1, e963447.	0.7	9
15	Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. <i>Science Signaling</i> , 2014, 7, ra29.	3.6	123
16	Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1935-1945.	7.0	121
17	Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. <i>Cancer Treatment Reviews</i> , 2012, 38, 698-707.	7.7	466
18	Impact of the delivery of adjuvant anthracycline-based nontaxane chemotherapy schedules on the outcome of breast cancer patients: Results from a retrospective database analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1074-1074.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Mechanisms of resistance to hormonal treatment in breast cancer. <i>Clinical and Translational Oncology</i> , 2010, 12, 246-252.	2.4	13
20	Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. <i>Cancer Treatment Reviews</i> , 2010, 36, 206-215.	7.7	228